Tag: InvestmentNews
-
Piramal Enterprises Invests Rs 600 Crore in its Subsidiary Piramal Finance Limited
The Rs 600-crore investment in Piramal Finance Limited signifies a strong commitment by Piramal Enterprises to solidify its financial services business. This strategic move enhances liquidity, strengthens operational capabilities, and ensures long-term growth potential. Investors and stakeholders should view this as a positive indicator of the company’s resilience and expansion strategy.
-
Patanjali Ayurved & DS Group to Acquire Magma General Insurance: A foray into the Insurance Sector
Patanjali Ayurved & DS Group are set to acquire Magma General Insurance from Sanoti Properties LLP for Rs 4,500 crore. This strategic move marks Patanjali’s entry into the general insurance sector. Read more about the impact and future implications of this deal.
-
Coromandel International picks up 53% stake in NACL Industries for Rs 820 crore
Coromandel International acquires a 53.13% stake in NACL Industries for Rs 820 crore, strengthening its agrochemical portfolio. Learn about the deal, its impact, and future prospects.
-
RPP Infra Secures Rs 109-Crore Order for Mega Leather Park Project in Tamil Nadu
Introduction: RPP Infra Projects has achieved another milestone by securing an order worth Rs 108.80 crore from the State Industries Promotion Corporation of Tamil Nadu (SIPCOT) for infrastructure development at […]
-
Piramal Alternatives Invests Rs 110 Crore in Biodeal Pharmaceuticals: A Strategic Boost for Innovation and Growth
Fueling Biodeal Pharmaceuticals' growth trajectory, Piramal Alternatives, the investment arm of the Piramal Group, has injected Rs 110 crore into the company. This strategic investment is poised to catapult Biodeal's capabilities, propelling it towards innovation, enhanced production, and expanded operations. With a focus on becoming a frontrunner in nasal spray manufacturing, Biodeal aims to leverage this infusion to fortify its infrastructure, adopt cutting-edge technology, and establish a state-of-the-art nutraceuticals facility. This collaboration signifies a significant milestone for both entities, marking a new chapter in the pharmaceutical landscape.